Correlation of Timing of Pegfilgrastim Administration and PIBP.

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Apr 21, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how the timing of a medication called pegfilgrastim affects the occurrence of bone pain in women undergoing chemotherapy for breast cancer. Pegfilgrastim is often used to help prevent infections during chemotherapy but can cause significant bone pain in some patients, which can impact their overall quality of life and treatment adherence. The trial aims to find out if giving pegfilgrastim at a different time can reduce the chances of experiencing this pain.

To participate in the trial, women between the ages of 18 and 70 with a confirmed diagnosis of primary breast cancer are eligible, provided they can receive chemotherapy as planned and understand the study requirements. Participants will be asked to complete questionnaires and provide consent to join the study. This research could help improve the experience of women undergoing chemotherapy by potentially reducing discomfort and ensuring they can complete their treatment more effectively.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Age greater than or equal to 18 years and less than or equal to 70 years.
• • 2. Pathologically or histologically confirmed diagnosis of primary breast cancer.
• • 3. Able to receive the chemotherapy regimen as scheduled.
• • 4. Able to understand Chinese and fill out the study-related questionnaires independently.
• • 5. Given written informed consent.
• • 6. There is no need to use prescription or over-the-counter drugs regularly because of pre-existing chronic pain.
• Exclusion Criteria:
• • 1. Suffering from bone pain due to other diseases currently.
• • 2. Allergy or contraindication to chemotherapeutic agents or pegfilgrastim.
• • 3. Previous use of pegfilgrastim.
• • 4. Previous received chemotherapy.
• • 5. Pregnancy or breastfeeding.
• • 6. Concurrently accompanied by other primary malignant tumors.